Pleural mesothelioma instigates tumor-associated fibroblasts to promote progression via a malignant cytokine network

American Journal of Pathology

Volumn 179, Issue 3, 2011, Pages 1483-1493

  Li, Qi ^a,b   Wang, Wei ^a,b   Yamada, Tadaaki ^a   Matsumoto, Kunio ^a   Sakai, Katsuya ^a   Bando, Yoshimi ^c   Uehara, Hisanori ^d   Nishioka, Yasuhiko ^d   Sone, Saburo ^d   Iwakiri, Shotaro ^e   Itoi, Kazumi ^e   Utsugi, Teruhiro ^f   Yasumoto, Kazuo ^a   Yano, Seiji ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c TOKUSHIMA UNIVERSITY HOSPITAL   (Japan)

^d UNIVERSITY OF TOKUSHIMA   (Japan)

^e HYOGO PREFECTURAL AMAGASAKI GENERAL MEDICAL CENTER   (Japan)

^f TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FIBROBLAST GROWTH FACTOR 2; IMATINIB; NK 4; ORANTINIB; SCATTER FACTOR; SMOOTH MUSCLE ACTIN; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL INFILTRATION; CELL INTERACTION; CELL MIGRATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FIBROBLAST; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; MALIGNANT PLEURAL MESOTHELIOMA; MOUSE; NONHUMAN; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR ASSOCIATED FIBROBLAST; TUMOR MICROENVIRONMENT;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CYTOKINES; FEMALE; FIBROBLAST GROWTH FACTOR 2; FIBROBLASTS; HEPATOCYTE GROWTH FACTOR; HUMANS; MALE; MESOTHELIOMA; MICE; MICE, SCID; MIDDLE AGED; NEOPLASM TRANSPLANTATION; PLATELET-DERIVED GROWTH FACTOR; PLEURAL NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; TUMOR MICROENVIRONMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80052838853     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2011.05.060     Document Type: Article

References (31)

1. M. Carbone, R.A. Kratzke, and J.R. Testa The pathogenesis of mesothelioma Semin Oncol 29 2002 2 17 (Pubitemid 34163530)
2. B.W. Robinson, and R.A. Lake Advances in malignant mesothelioma N Engl J Med 353 2005 1591 1603 (Pubitemid 41434638)
3. J. Aisner Current approach to malignant mesothelioma of the pleura Chest 107 1995 332S 344S
4. N.J. Vogelzang, J.J. Rusthoven, J. Symanowski, C. Denham, E. Kaukel, P. Ruffie, U. Gatzemeier, M. Boyer, S. Emri, C. Manegold, C. Niyikiza, and P. Paoletti Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma J Clin Oncol 21 2003 2636 2644 (Pubitemid 46606305)
5. N.A. Bhowmick, E.G. Neilson, and H.L. Moses Stromal fibroblasts in cancer initiation and progression Nature 432 2004 332 337 (Pubitemid 39551661)
6. S.S. McAllister, A.M. Gifford, A.L. Greiner, S.P. Kelleher, M.P. Saelzler, T.A. Ince, F. Reinhardt, L.N. Harris, B.L. Hylander, E.A. Repasky, and R.A. Weinberg Systemic endocrine instigation of indolent tumor growth requires osteopontin Cell 133 2008 994 1005 (Pubitemid 351787747)
7. W. Wang, Q. Li, T. Yamada, K. Matsumoto, I. Matsumoto, M. Oda, G. Watanabe, Y. Kayano, Y. Nishioka, S. Sone, and S. Yano Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors Clin Cancer Res 15 2009 6630 6638
8. L.B. Saltz, S. Clarke, E. Díaz-Rubio, W. Scheithauer, A. Figer, R. Wong, S. Koski, M. Lichinitser, T.S. Yang, F. Rivera, F. Couture, F. Sirzén, and J. Cassidy Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2008 2013 2019
9. A. Sandler, R. Gray, M.C. Perry, J. Brahmer, J.H. Schiller, A. Dowlati, R. Lilenbaum, and D.H. Johnson Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2006 2542 2550 (Pubitemid 44917502)
10. A.M. Araujo Pemetrexed plus bevacizumab for second-line therapy of non-small-cell lung cancer: the importance of patient selection J Clin Oncol 28 2010 e131 author reply e132
11. L.S. Rosen, D. Gordon, S. Tchekmedyian, R. Yanagihara, V. Hirsh, M. Krzakowski, M. Pawlicki, P. de Souza, M. Zheng, G. Urbanowitz, D. Reitsma, and J. Seaman Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trialthe Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group J Clin Oncol 21 2003 3150 3157 (Pubitemid 46606297)
12. Q. Li, S. Yano, H. Ogino, W. Wang, H. Uehara, Y. Nishioka, and S. Sone The therapeutic efficacy of anti vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice Clin Cancer Res 13 2007 5918 5925 (Pubitemid 47583920)
13. C.J. Baglole, D.M. Ray, S.H. Bernstein, S.E. Feldon, T.J. Smith, P.J. Sime, and R.P. Phipps More than structural cells, fibroblasts create and orchestrate the tumor microenvironment Immunol Invest 35 2006 297 325 (Pubitemid 44266778)
14. P. Harvey, A. Warn, P. Newman, L.J. Perry, R.Y. Ball, and R.M. Warn Immunoreactivity for hepatocyte growth factor/scatter factor and its receptor, met, in human lung carcinomas and malignant mesotheliomas J Pathol 180 1996 389 394 (Pubitemid 27014076)
15. S. Kato, H. Funakoshi, T. Nakamura, M. Kato, I. Nakano, A. Hirano, and E. Ohama Expression of hepatocyte growth factor and c-Met in the anterior horn cells of the spinal cord in the patients with amyotrophic lateral sclerosis (ALS): immunohistochemical studies on sporadic ALS and familial ALS with superoxide dismutase 1 gene mutation Acta Neuropathol 106 2003 112 120 (Pubitemid 36869244)
16. T. Nakamura, K. Sakai, and K. Matsumoto Anti-cancer approach with NK4: bivalent action and mechanisms Anticancer Agents Med Chem 10 2010 36 46
17. A. Albini, Y. Iwamoto, H.K. Kleinman, G.R. Martin, S.A. Aaronson, J.M. Kozlowski, and R.N. McEwan A rapid in vitro assay for quantitating the invasive potential of tumor cells Cancer Res 47 1987 3239 3245 (Pubitemid 17082655)
18. S. Yano, W. Wang, Q. Li, K. Matsumoto, H. Sakurama, T. Nakamura, H. Ogino, S. Kakiuchi, M. Hanibuchi, Y. Nishioka, H. Uehara, T. Mitsudomi, Y. Yatabe, and S. Sone Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations Cancer Res 68 2008 9479 9487
19. E. Nakataki, S. Yano, Y. Matsumori, H. Goto, S. Kakiuchi, H. Muguruma, Y. Bando, H. Uehara, H. Hamada, K. Kito, A. Yokoyama, and S. Sone Novel orthotopic implantation model of human malignant pleural mesothelioma (EHMES-10 cells) highly expressing vascular endothelial growth factor and its receptor Cancer Sci 97 2006 183 191
20. T. Yamada, K. Matsumoto, W. Wang, Q. Li, Y. Nishioka, Y. Sekido, S. Sone, and S. Yano Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer Clin Cancer Res 16 2010 174 183
21. T. Nakamura, T. Nishizawa, M. Hagiya, T. Seki, M. Shimonishi, A. Sugimura, K. Tashiro, and S. Shimizu Molecular cloning and expression of human hepatocyte growth factor Nature 342 1989 440 443 (Pubitemid 19277521)
22. L. Strizzi, G. Vianale, A. Catalano, R. Muraro, L. Mutti, and A. Procopio Basic fibroblast growth factor in mesothelioma pleural effusions: correlation with patient survival and angiogenesis Int J Oncol 18 2001 1093 1098
23. P. Bertino, F. Piccardi, C. Porta, R. Favoni, M. Cilli, L. Mutti, and G. Gaudino Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts Clin Cancer Res 14 2008 541 548 (Pubitemid 351226124)
24. G. Eagles, A. Warn, R.Y. Ball, H. Baillie-Johnson, N. Arakaki, Y. Daikuhara, and R.M. Warn Hepatocyte growth factor/scatter factor is present in most pleural effusion fluids from cancer patients Br J Cancer 73 1996 377 381 (Pubitemid 26047517)
25. P. Harvey, A. Warn, S. Dobbin, N. Arakaki, Y. Daikuhara, M.C. Jaurand, and R.M. Warn Expression of HGF/SF in mesothelioma cell lines and its effects on cell motility, proliferation and morphology Br J Cancer 77 1998 1052 1059 (Pubitemid 28116274)
26. T. Burgess, A. Coxon, S. Meyer, J. Sun, K. Rex, T. Tsuruda, Q. Chen, S.Y. Ho, L. Li, S. Kaufman, K. McDorman, R.C. Cattley, G. Elliott, K. Zhang, X. Feng, X.C. Jia, L. Green, R. Radinsky, and R. Kendall Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors Cancer Res 66 2006 1721 1729 (Pubitemid 43259957)
27. S. Previdi, P. Maroni, E. Matteucci, M. Broggini, P. Bendinelli, and M.A. Desiderio Interaction between human-breast cancer metastasis and bone microenvironment through activated hepatocyte growth factor/Met and beta-catenin/Wnt pathways Eur J Cancer 46 2010 1679 1691
28. Y. Suzuki, K. Sakai, J. Ueki, Q. Xu, T. Nakamura, H. Shimada, and K. Matsumoto Inhibition of Met/HGF receptor and angiogenesis by NK4 leads to suppression of tumor growth and migration in malignant pleural mesothelioma Int J Cancer 127 2010 1948 1957
29. C. Porta, L. Mutti, and G. Tassi Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma Cancer Chemother Pharmacol 59 2007 149 150 (Pubitemid 44796113)
30. A. Mathy, P. Baas, O. Dalesio, and N. van Zandwijk Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial Lung Cancer 50 2005 83 86 (Pubitemid 41297473)
31. S. Yano, H. Shinohara, R.S. Herbst, H. Kuniyasu, C.D. Bucana, L.M. Ellis, and I.J. Fidler Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells Am J Pathol 157 2000 1893 1903